Recurrence Monitoring in NSCLC Using Circulating Tumor DNA

NCT03878537 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-03-23

No results posted yet for this study

Summary

This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.

Conditions

  • Non Small Cell Lung Cancer

Sponsors & Collaborators

  • Scripps Health

    collaborator OTHER
  • Lexent Bio, Inc.

    collaborator INDUSTRY
  • Scripps Translational Science Institute

    lead OTHER

Principal Investigators

  • Marin Xavier · Scripps Health

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-14
Primary Completion
2021-03-01
Completion
2021-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03878537 on ClinicalTrials.gov